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Abstract
Background: To evaluate the impact of diabetes on outcomes in colorectal cancer patients and to examine whether this
association varies by the location of tumor (colon vs. rectum).
Patients and methods: This study includes 4,131 stage I-III colorectal cancer patients, treated between 1995 and 2007
(12.5% diabetic, 53% colon, 47% rectal) in South Korea. Cox proportional hazards modeling was used to determine the
prognostic influence of DM on survival endpoints.
Results: Colorectal cancer patients with DM had significantly worse disease-free survival (DFS) [hazard ratio (HR) 1.17, 95%
confidence interval (CI): 1.00–1.37] compared with patients without DM. When considering colon and rectal cancer
independently, DM was significantly associated with worse overall survival (OS) (HR: 1.46, 95% CI: 1.11–1.92), DFS (HR: 1.45,
95% CI: 1.15–1.84) and recurrence-free survival (RFS) (HR: 1.32, 95% CI: 0.98–1.76) in colon cancer patients. No association for
OS, DFS or RFS was observed in rectal cancer patients. There was significant interaction of location of tumor (colon vs. rectal
cancer) with DM on OS (P=0.009) and DFS (P=0.007).
Conclusions: This study suggests that DM negatively impacts survival outcomes of patients with colon cancer but not rectal
cancer.
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Introduction
Colorectal cancer is the fourth most common cancer in the
United States [1], fourth in men and third in women worldwide
[2]. Although the incidence rate of colorectal cancer has increased
rapidly worldwide during the last two decades, the incidence rate
varies 10-fold among regions of the world, with the highest rates
being estimated in developed countries and lowest rates in
developing and underdeveloped countries [3]. Interestingly, many
regions including Asia, which used to have low incidence of
colorectal cancer now have significantly increased incidence of
colorectal cancer. In South Korea, for example, the incidence of
colorectal cancer increased significantly from 21.2 per 100,000 in
1999 to 42.1 per 100,000 in 2007 [4]. The change in lifestyle and
especially increase in obesity contribute to such rapid increase in
the incidence of colorectal cancer [5].
It has been well established that obesity influences the incidence
of colorectal cancer [6,7]. Obesity and associated insulin resistance
are two common contributors to the development of both type 2
DM and cancer and it is not surprising to observe increased risk of
colorectal cancer in type 2 diabetic patients [8–10]. The
pathological explanation for this connection has led to a so-called
hyperinsulinemia hypothesis [11]; increased insulin level could
promote colorectal tumor growth and act as a cell mitogen [12]. In
support of this hypothesis, positive association between serum C-
peptide concentration and an increased colorectal cancer risk were
found in several studies [13–15]. Although studies have reported a
clear association of DM and hyperinsulinemia with the risk of
colorectal cancer [16], association between DM and the risk of
mortality in colorectal cancer patients is somewhat unclear.
Historically, colon and rectal cancers have been considered
together; however, the etiology and risk factors may differ among
proximal colon, distal colon and rectal cancer. Indeed, several
studies [17–20] have reported that DM was associated with the
risk of proximal colon but not with distal and rectal cancers. Until
now, most studies which evaluated the association between DM
and the risk of mortality either included only colon cancer patients
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together [25–27]. Very rarely, studies report the association
between DM and the risk of mortality in rectal cancer patients
separate from colon cancer. This could be due to relatively lower
incidence of rectal cancer than colon cancer in Western countries
[28], where most studies which investigated the association
between DM and the risk of mortality in colorectal cancer
patients were conducted. Furthermore, to our knowledge, the risk
of mortality according to the site of colon cancer (proximal vs.
distal colon) with and without DM has not been studied. Only one
other study reported the association between DM and oncologic
outcomes in an Asian population [23], important because the
impact of DM on colorectal cancer outcomes could differ by race.
With growing interest in and evidence of the relationship between
DM and colorectal cancer outcomes, it is important to study the
effects of DM on the risk of mortality according to the specific site
of cancers in the colon and rectum in Asian population. Therefore,
the purpose of this study is to investigate the impact of DM on
oncologic outcomes in stage I-III colorectal cancer patients and to
examine whether this association varies by the site of colorectal
cancer (colon vs. rectum).
Patients and Methods
Ethics Statement
All study procedures were reviewed and approved by the
Institutional Ethics Review Board at the Shinchon Severance
Hospital and conducted according to the principles expressed in
the Declaration of Helsinki. Informed consent was exempted by
the board due to the retrospective nature of this research.
Study Cohort
The prospective data base used in the current study is from a
single hospital (Severance Hospital, Seoul, South Korea), which
included data from patients who underwent colon or rectal cancer
surgery for Stage I–III disease between January 4
th 1995 and
December 31
st 2007. The data base included anthropometric
measurements, date and methods of surgery, size of tumor, lymph
node status, family history of colorectal cancer, site of primary
tumor, carcinoembryonic antigen (CEA) levels, adjuvant or
neoadjuvant chemotherapy regimen, radiation therapy dose and
site (if applicable), date of recurrence and date of death. Using the
prospectively collected database, 4162 potential patients who
underwent resection for histologically proven adenocarcinoma of
the colon and rectal cancer were considered for this study. We
excluded patients aged over 90 year old (N=5) and aged less than
18 year old (N=1). In addition, subjects whose mortality
information was missing (N=25) were excluded from the analyses.
Thus, a total of 4131 subjects were included in our study analysis.
The participants were followed until October 2011.
Study Design
Patients either had DM listed in their medical history or had a
DM-controlling medication listed among their medication at the
time of colorectal cancer surgery were classified as diabetic. With
this method, we could not distinguish whether patients had type 1
or type 2 DM and the study thus includes both type 1 and type 2
DM. However, the incidence of type 1 DM is 1.36 (95% CI 1.05–
1.66) cases per year per 100,000 individuals, which is approxi-
mately 10% of that in the United States [29]. Therefore, most
diabetic patients in the data base are most likely type 2 diabetics.
The primary end point of this analysis was overall survival and
the secondary outcomes were disease-free survival, recurrence-free
survival and colorectal cancer-specific survival. Overall survival
was defined as the time from the date of surgery to death from any
cause. Disease-free survival was defined as time from the date of
surgery to tumor recurrence or occurrence of a new primary
colorectal tumor or death from any cause. In addition, we defined
recurrence-free survival as the time from the surgery to tumor
recurrence or occurrence of a new primary colon tumor. For
recurrence-free survival, patients who died without known tumor
recurrence were censored. Colorectal specific-survival was defined
as the time from the date of surgery to death from colorectal
cancer-specific cause of death. In colorectal cancer-specific
survival analyses, death as a result of other causes were censored.
Patients were followed every three months for the first two years
after surgery, every 6 months in years 2–5, then annually. Study
outcomes were ascertained until October 31
st 2011 through
linkage to the hospital data base and the National Death Registry.
Patients who remained alive at the end of the follow-up period
were censored.
Statistical Analysis
The Kaplan-Meier method and log-rank test were used for
overall survival, disease-free survival and colorectal cancer-specific
mortality. Survival analysis assessed deaths as a result of all-causes,
colorectal cancer-specific mortality as well as disease- and
recurrence-free survival. Age-adjusted and multivariable-adjusted
hazard ratio (HR) and 95% CIs were calculated using Cox
proportional hazards models to determine the prognostic influence
of DM on survival endpoints. Participants without documented
and/or treated DM were used a reference group for all analyses.
Covariates include age (continuous) at diagnosis, gender, body
mass index (BMI) (continuous), family history of colorectal cancer
in first degree relatives (Yes, No), TNM stage (I, II and III),
adjuvant therapy (No adjuvant therapy, Chemotherapy only,
Radiation therapy only, Chemotherapy and radiation therapy
together), and the year of surgery (continuous) were extracted from
medical record. Interaction was assessed using the Wald test on the
cross-product of DM and other variables of interest (Age, gender,
BMI, stage of disease- and site-specific effects) in a multivariate
model. All P values were two sided. P,0.05 was considered
statistically significant. All statistical analyses were performed using
SAS 9.1 statistical software package.
Results
Baseline Characteristics
The mean age of the 4131 participants was 59611.4 year old
with mean BMI of 2363.1 kg/m
2. Out of 4131 participants, 517
participants (12.5%) had preexisting DM prior to cancer diagnosis.
Compared with subjects without DM, subjects with DM were
significantly older (P,0.001) and had higher BMI (P,0.001).
During the follow up period, there were a total of 1037 (467 colon
cancer, 570 rectal cancer) deaths, 951 recurrences (411 colon
cancer, 540 rectal cancer) and 679 colorectal cancer-specific
deaths (285 colon cancer, 394 rectal cancer). Baseline character-
istics are summarized in table 1.
Effects of DM on the Risk of Mortality Colon and Rectal
Cancer Patients
In Cox proportional hazard models, we examine the influence
of DM on the risk of overall survival, disease-free survival,
recurrence-free survival and colorectal cancer-specific survival
controlling for factors associated with cancer survival (Figure 1,
Table 2). There was a significant association between presence of
DM and multivariate adjusted disease-free survival (HR: 1.17,
95% CI: 1.00–1.37). In contrast, there was no significant
Site Specific Effects of DM on Colorectal Cancer
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overall survival, recurrence-free survival and colorectal cancer-
specific survival. To better understand the association of DM and
the risk of mortality according to the site of primary tumor, we
analyzed colon and rectal cancer patients separately (Figure 1).
After adjustment for potential confounders, colon cancer patients
with preexisting DM experienced significantly worse overall
survival (HR: 1.46, 95%CI: 1.11–1.92), disease-free survival
(HR: 1.45, 95% CI: 1.15–1.84) and nonsignificant trend towards
worse recurrence-free survival (HR: 1.32, 95%, CI: 0.98–1.76).
Preexisting DM was not associated with colon cancer-specific
survival (HR: 1.25, 95% CI: 0.87–1.80). In contrast, there was no
association between DM and outcome of rectal cancer patients in
any of the study end points. There was significant interaction
between location of primary tumor (colon vs. rectum) with DM on
overall survival (P=0.0094) and disease-free survival (P=0.0068).
No difference in the use of chemotherapy (P=0.30) or radiation
therapy (P=0.55) between rectal cancer patients with and without
DM was observed.
To further understand this effect by the location of colon tumor
site, we further tested the association between DM and outcomes
in patients with proximal and distal colon cancer. DM was
associated with overall survival in patients with proximal colon
cancer (HR: 2.08, 95% CI: 1.38–3.13) but not in patients with
distal colon cancer (HR: 1.34, 95% CI: 0.92–1.96) (Table 3). The
P for interaction was not statistically significant (P=0.108).
Table 1. Subject characteristics.
Colon Cancer (N=2183) Rectal Cancer (N=1948)
No DM DM No DM DM
(N=1895) (N=288) (N=1719) (N=229)
Sex (Male/Female) 1091/804 181/107 1059/660 148/81
Age (year6SD) 59.1611.6 64.068.8* 58.2611.6 62.468.8*
#50 378(19.9) 18 (6.3) 391 (22.7) 13 (5.7)
51 to #60 526 (27.8) 57 (19.8) 482 (28.0) 72 (31.4)
61 to #70 643 (33.9) 139 (48.3) 562 (32.7) 93 (40.6)
.70 348 (18.4) 74(25.7) 284 (16.5) 51 (22.3)
BMI (kg/m
2 mean6SD) 23.063.1 23.663.3 23.063.1 23.763.2
,18.5 109 (5.8) 9 (3.1) 107 (6.2) 8 (3.5)
18.5 to ,23 766 (40.4) 101 (35.1) 704 (41.0) 78 (34.1)
23 to ,25 412 (21.7) 67 (23.3) 377 (21.9) 59 (25.8)
$25 418 (22.1) 85 (29.5) 381 (22.2) 68 (29.7)
Missing 190 (10.0) 26 (9.0) 150 (8.7) 16 (7)
Family history (Yes %) 84 (4.4) 10 (3.5) 54 (3.1) 2 (0.9)
TNM stage
I 302 (15.9) 47 (16.3) 468 (27.2) 59(25.8)
II 882 (46.5) 133 (46.2) 531 (30.9) 71 (31.0)
III 711 (37.5) 108 (37.5) 720 (41.9) 99 (43.2)
No positive lymph node
0 1182 (62.4) 180(62.5) 995 (57.9) 131 (57.2)
1 to 4 554 (29.2) 83 (28.9) 495 (28.8) 77 (33.6)
$5 156 (8.2) 25 (8.7) 225(13.1) 21 (9.2)
Missing 3 (0.2) 0 4 (0.2) 0
Preoperative CEA
,5 ng/dl 1406(74.2) 186 (64.6) 1288(74.9) 148(64.6)
$5 ng/dl 479 (25.3) 101 (35.1) 424(24.7) 81(35.4)
Missing 10 (0.5) 1 (.3) 7(0.4) 0
Adjuvant therapy
No 445 (23.5) 69 (24.0) 450 (26.2) 61 (26.6)
Chemotherapy alone 1237 (65.3) 192 (66.7) 444 (25.8) 56 (24.5)
Radiation alone 4 (.2) 0 (0) 35 (2.0) 9 (3.9)
Chemo and radiation 90 (4.7) 11 (3.8) 719 (41.8) 92 (40.2)
Missing 119 (6.3) 16(5.6) 71(4.1) 11 (4.8)
SD: Standard deviation, Number (%), DM: Diabetes Mellitus, * p,0.05 Significantly different compared with subjects who did not have DM.
doi:10.1371/journal.pone.0055196.t001
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Colon Cancer
In light of the significant association between DM and survival
endpoints in colon cancer, we examined the association with DM
across strata of potential predictors of survival outcomes including
gender, age, BMI and TNM stage (Table 3). The association
between pre-existing DM and survival endpoints in colon cancer
patients was not modified by gender (P=0.828), BMI (P=0.672),
TNM stage (stage I/II versus III, P=0.369) and age (P=0.169).
Discussion
Among participants in this large cohort of Korean adults with
stage I to III colorectal cancer, patients with DM experience
significantly worse disease-free survival compared to non-diabetics,
and nonsignificant trend towards worse recurrence-free survival
and overall survival. However, when site of disease was
considered, DM was associated with a significantly worse overall
survival, disease-free survival and near significant recurrence-free
survival (P=0.065) in colon cancer patients, with no association in
rectal cancer patients, suggesting that DM negatively affects the
survival outcome of colon cancer patients, however, DM does not
affect survival outcome of rectal cancer.
The question of the association between DM and survival
outcomes in colorectal cancer patients has been previously studied,
with several studies reporting a significant detrimental impact
[22,26,30] while others have not demonstrated such associations
[21,25,27]. Considering distinct differences in anatomy, embryol-
ogy, physiology and genetics of colon and rectal cancer, studying
the impact of DM on survival outcome of colon and rectal cancer
patients together may not be appropriate. Most studies to date
have not analyzed the relationship between DM and cancer
outcomes separately in colon and rectal cancer populations with
adequate subgroup sample sizes. Several prospective studies have
demonstrated that DM is associated more with the risk of either
colon or proximal colon cancer than rectal cancer [17,31–33].
There was an only one prior study which studied the association of
DM and survival outcome separately by colon and rectal cancer
[34]. Van de Poll-Franse et al. [34] found significant association
between preexisting DM and the risk of mortality in both colon
and rectal cancer patients. It is unclear why there is discrepancy in
results between the study of Van de Poll-Franse [34] and the
current study. One possible explanation could include the racial
differences between the two studies. Additionally, Van de Poll-
Franse [34] reported that less aggressive treatment regimen was
adopted for cancer patients with DM compared with patients who
did not have DM. Although rectal cancer patients with DM were
Figure 1. Kaplan-Meier survival curve for disease-free survival in colorectal (A), colon (B) and rectal (C) cancer patients staged I to III
by diabetes mellitus status.
doi:10.1371/journal.pone.0055196.g001
Site Specific Effects of DM on Colorectal Cancer
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patients with DM from the study of Van de Poll-Franse et al. [34]
were older than patients from the current study (71.6 vs. 62 years)
and this may explain the possibility of less aggressive cancer
treatment implemented in their study. Another interesting study
reported that neoadjuvant chemotherapy in rectal cancer was less
effective in diabetic patients than in non-diabetic patients possibly
due to difference in pathologic response [35]. However, we did not
observe any difference in oncologic outcome in rectal cancer
patients with and without DM. In the current study, there was no
difference in chemo and radiation therapy regimen between rectal
cancer patients with and without DM.
In the current study, we have found stronger association
between DM and survival outcome in patients with proximal
colon cancer than distal colon cancer and no association between
DM and survival outcome in patients with rectal cancer. It is
unclear why DM was associated more with the outcomes of
proximal colon cancer than with distal colon and rectal cancer.
The potential mechanisms for different effects of DM on proximal,
distal colon and rectal cancer could include different character-
istics of tumor microsatellite instability status as well as chromo-
somal instability association to proximal and distal colon [20].
Considering more proximal site colon tumors (30–40%) than distal
colon or rectal tumors (3–12%) have higher levels of methylated
CpG islands in several tumor suppressor genes or inactivated
ncRNA, worse prognosis of proximal cancer patients with DM in
our study could also be associated with epigenetics which may
interact between DM and tumor according to its sites [36,37].
Furthermore, different characteristics of risk factors such as
adiposity, diet and physical activity on proximal, distal colon
and rectal tumor characteristics [38–40] may explain the different
impact of DM on site-specific oncologic outcomes. The mecha-
nism why DM was associated with colon cancer and not rectal
cancer deserve more research studies since two recently reported
meta-analysis studies showed that DM was associated with
increased incident of both colon and rectal cancer [41–42].
However, this is the beyond the scope of the current study and
deserve further studies.
A study of Polednak [43] raised an important question: DM
could increase the all-cause mortality of colon and colorectal
cancer patients, but DM may not increase the risk of colorectal
cancer-specific death. In his study, he reported a 38% increased
risk of all-cause mortality among colorectal cancer with DM.
However, when he performed sub-analysis according to the cause
of mortality, no association between DM and the risk of colorectal-
specific mortality. In our study, we also found that DM was
significantly associated with worse overall and disease-free survival
but not with colon cancer-specific survival in colon cancer
patients. Therefore, one may ask question whether DM would
impact actual tumor recurrence or DM would increase risk of
mortality from other causes such as cardiovascular disease. The
risk of cancer recurrence was 35 percent higher in colon cancer
patients with DM (HR: 1.35:95% CI: 1.04–1.77) when age and
gender were controlled. When other covariates were also
controlled, the risk of recurrence was 32 percent higher in colon
cancer with DM although it was not statistically significant (HR:
1.32, 95% CI: 0.98–1.76). Considering the study from Dehal et al.
[44] which recently reported significantly increased cardiovascular
disease-specific death in colorectal cancer patients who had DM,
we may speculate that the impact of DM on mortality of colon
cancer patients may be due to both recurrence of disease and
death from other causes.
Although the presence of DM was not associated with oncologic
outcome of rectal cancer, it was evident that the DM was
associated with oncologic outcome of colon cancer [45]. Several
mechanisms have been proposed to explain the link between type
2 DM and colorectal cancer including the insulin-like growth
factor (IGF-1)-hyperinsulinemia theory which implies that elevated
insulin and free IGF-1 levels increase the proliferation and
decrease the apoptosis of colon cancer cells [46–47], which
Table 3. Impact of DM on outcome of overall survival of
stage 1 to 3 colon cancer patients according to their BMI, TNM
stage, age and site of cancer (proximal vs distal).
Non DM DM Ptrend Pinteraction
Risk of overall survival
Male
No at risk/events 1091/234 181/49
MV adjusted (95% CI) 1.00 (Ref) 1.45 (1.02–2.06) 0.038
Female 0.828
No at risk/events 804/154 107/30
MV adjusted (95% CI) 1.00 (Ref) 1.48 (0.96–2.30) 0.075
BMI specific effects of DM ˆ
BMI ,23 kg/m
2
No at risk/events 877/186 109/29
MV adjusted (95% CI) 1.00 (Ref) 1.48 (1.06–2.05) 0.02
BMI .23 kg/m
2 0.672
No at risk/events 828/141 153/36
MV adjusted (95% CI) 1.00 (Ref) 1.52 (1.04–2.21) 0.031
Stage specific effects of DM
TNM Stage I/II
No at risk/events 1184/174 180/43
MV adjusted (95% CI) 1.00 (Ref) 1.38 (1.05–1.81) 0.019
TNM Stage III 0.369
No at risk/events 711/214 108/36
MV adjusted (95% CI) 1.00 (Ref) 1.25 (0.84–1.85) 0.269
Age specific effects of DM
Age ,60 years
No at risk/events 977/145 89/20
MV adjusted (95% CI) 1.00 (Ref) 2.04 (1.17–3.54) 0.012
Age$60 years 0.169
No at risk/events 918/243 199/59
MV adjusted (95% CI) 1.00 (Ref) 1.43 (1.04–1.96) 0.026
Site Specific effects of DM *
Proximal Colon
No at risk/events 798/170 128/39
MV adjusted (95% CI) 1.00 (Ref) 2.08 (1.38–3.13) .0.001
Distal Colon 0.108
No at risk/events 1073/215 153/37
MV adjusted (95% CI) 1.00 (Ref) 1.34 (0.92–1.96) 0.12
DM: Diabetes mellitus, CI: Confidence Interval, BMI: Body mass index, MV:
Multivariate, MV adjusted: Gender, BMI, TNM stage, family history of colorectal
cancer (yes or no), Adjuvant therapy (No, Chemotherapy only, Radiation
therapy only, Chemotherapy and radiation therapy together), the year of
surgery,
ˆ216 case were not included due to missing BMI information,
*31 cases were not included due to missing information on the site specific
location (proximal vs distal).
doi:10.1371/journal.pone.0055196.t003
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signal regulated kinase, phosphatidylinositol-3-kinase, protein
kinase B and mammalian target of rapamycin (mTOR). Another
possible mechanism which links DM and colorectal cancer
oncologic outcome may include altered inflammatory and anti-
inflammatory cytokines in type 2 diabetic patients, which may
influence the oncologic outcome of colon cancer [48–49].
There are limitations and strengths of the study. First, DM
status was based on the past medical history and thus types of DM
were not differentiated between type 1 and type 2. However, given
the average age of the study participants with DM was 63 years old
and the lower incidence of type 1 DM in Korea, most diabetic
patients in our study would be type 2 diabetics. Furthermore, our
cohort cannot address the potential of undiagnosed hyperglycemic
states or DM in the control population; however, such contam-
ination would only bias our findings towards the null hypothesis.
Recent studies showed that diabetic medications and use of insulin
therapy are associated with the risk and outcome or colorectal
cancer patients [50–52]. However, the current study does not have
patients’ medication as well as glycemic control data and this is the
another limitation of the current study. Furthermore, the data on
the use of aspirin, non-aspirin nonsteroidal anti-inflammatory
drugs and cyclooxygenase-2 inhibitor in our patients was not
available and therefore the use of these medications was not
controlled.
In conclusion, we found significantly reduced overall and
disease-free survival only in colon cancer but not in rectal patients
with DM. In our knowledge, this was the first study to report the
association between DM and the risk of mortality was dependent
on the site of tumor (Proximal colon, distal colon and rectal
cancer) in colorectal cancer.
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